X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2193) 2193
Book Review (398) 398
Publication (162) 162
Book Chapter (27) 27
Book / eBook (6) 6
Conference Proceeding (5) 5
Dissertation (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1837) 1837
humans (1817) 1817
female (1716) 1716
ovarian neoplasms - pathology (1122) 1122
middle aged (953) 953
adult (866) 866
oncology (808) 808
aged (749) 749
ovarian cancer (747) 747
cancer (671) 671
pathology (655) 655
cystadenocarcinoma, serous - pathology (574) 574
obstetrics & gynecology (545) 545
carcinoma (529) 529
prognosis (498) 498
tumors (482) 482
ovarian neoplasms - genetics (451) 451
neoplasm staging (446) 446
immunohistochemistry (418) 418
aged, 80 and over (348) 348
ovarian neoplasms - metabolism (336) 336
surgery (280) 280
ovary (278) 278
retrospective studies (271) 271
ovarian neoplasms - surgery (257) 257
cystadenocarcinoma, serous - genetics (247) 247
expression (238) 238
serous carcinoma (238) 238
mutation (231) 231
diagnosis (225) 225
adolescent (221) 221
cystadenocarcinoma, serous - metabolism (221) 221
ovarian neoplasms - mortality (219) 219
analysis (214) 214
ovarian neoplasms - diagnosis (214) 214
cystadenoma, serous - pathology (208) 208
young adult (208) 208
survival (202) 202
research (201) 201
borderline tumors (197) 197
chemotherapy (184) 184
diagnosis, differential (181) 181
abridged index medicus (166) 166
women (161) 161
ovarian carcinoma (154) 154
neoplasm grading (153) 153
endocrine system diseases (152) 152
follow-up studies (152) 152
neoplasm invasiveness (150) 150
adenocarcinoma, mucinous - pathology (149) 149
metastasis (148) 148
obstetrics and gynecology (146) 146
risk factors (146) 146
neoplasms (145) 145
survival rate (142) 142
biomarkers, tumor - analysis (141) 141
male (141) 141
medicine & public health (140) 140
serous borderline tumors (139) 139
cystadenocarcinoma, serous - surgery (134) 134
treatment outcome (133) 133
health aspects (129) 129
biomarkers, tumor - metabolism (128) 128
genetic aspects (128) 128
care and treatment (126) 126
mutations (126) 126
hematology, oncology and palliative medicine (125) 125
carcinoma, ovarian epithelial (124) 124
ovarian neoplasms - therapy (124) 124
neoplasms, cystic, mucinous, and serous - pathology (122) 122
serous tumors (122) 122
neoplasms, glandular and epithelial - pathology (121) 121
p53 (121) 121
pathogenesis (120) 120
gene expression (119) 119
gene expression regulation, neoplastic (116) 116
fallopian-tube (115) 115
article (114) 114
carcinoma - pathology (114) 114
carcinoma, endometrioid - pathology (114) 114
ovarian neoplasms - drug therapy (112) 112
cell biology (111) 111
development and progression (110) 110
female genital diseases and pregnancy complications (109) 109
peritoneal implants (109) 109
cystadenocarcinoma, serous - mortality (108) 108
management (108) 108
proteins (108) 108
adenocarcinoma (107) 107
cystadenocarcinoma, serous - diagnosis (107) 107
breast-cancer (106) 106
epithelial tumors (106) 106
serous borderline tumor (103) 103
survival analysis (103) 103
malignancy (102) 102
disease-free survival (98) 98
peritoneal neoplasms - pathology (98) 98
low-grade (97) 97
ovary - pathology (95) 95
adenocarcinoma, clear cell - pathology (94) 94
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2087) 2087
Chinese (48) 48
German (31) 31
French (22) 22
Korean (8) 8
Japanese (5) 5
Polish (5) 5
Spanish (5) 5
Romanian (4) 4
Russian (3) 3
Bulgarian (2) 2
Hungarian (2) 2
Danish (1) 1
Hebrew (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 05/2013, Volume 49, Issue 8, pp. 1905 - 1914
Journal Article
Journal Article
International Journal of Gynecologic Cancer, ISSN 1048-891X, 03/2019, Volume 29, Issue 3, pp. 572 - 578
AimTo compare distinct clinicopathological features between atypical proliferative serous tumors and non-invasive low-grade ovarian serous... 
ovary | serous borderline tumors | ENDOSALPINGIOSIS | LYMPH-NODE INVOLVEMENT | IMPACT | ONCOLOGY | PROGNOSIS | CARCINOMAS | CLASSIFICATION | PATHOLOGY | IMPLANTS | DIAGNOSTIC-CRITERIA | OBSTETRICS & GYNECOLOGY | Index Medicus
Journal Article
The Journal of Pathology, ISSN 0022-3417, 12/2013, Volume 231, Issue 4, pp. 449 - 456
BRAF and KRAS mutations in ovarian serous borderline tumours ( OSBTs ) and ovarian low‐grade serous carcinomas ( LGSCs ) have been previously described.... 
mutation | deep sequencing | ovarian low‐grade serous carcinoma | KRAS | BRAF | serous borderline tumour | COLD‐PCR | COLD-PCR | ovarian low-grade serous carcinoma | SURVIVAL | NEOPLASMS | IMPLANTS | PATHOLOGY | PATHOGENESIS | CANCER GENOMICS | ONCOLOGY | RAS MUTATIONS | PROTEIN MUTATIONS | EXPRESSION | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Humans | Middle Aged | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - pathology | DNA Mutational Analysis - methods | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Adult | Female | Cell Death - drug effects | Tumor Cells, Cultured | High-Throughput Nucleotide Sequencing - methods | MAP Kinase Kinase Kinases - antagonists & inhibitors | Neoplasm Proteins - genetics | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Proto-Oncogene Proteins B-raf - genetics | Benzimidazoles - pharmacology | Neoplasm Recurrence, Local - genetics | Aged | Protein Kinase Inhibitors - pharmacology | DNA, Neoplasm - genetics | Mutation | Cystadenoma, Serous - genetics | Cystadenoma, Serous - pathology | Proteins | Relapse | Carcinoma | Gene mutations | Genomics | Analysis | Denaturation | Cancer | Diseases | Index Medicus | KRAS mutation | Ovarian low-grade serous carcinoma | Serous borderline tumor | Deep sequencing | KRAS G12V | BRAF mutation | Full COLD-PCR
Journal Article
Journal Article
Journal Article